

MOCA Message

July 2026 Highlights

MOCA Message - July 2026

Welcome to the MOCA Message - keeping PMA members informed and connected to ongoing efforts to support the continued, responsible use of MOCA. Through these messages, we'll share progress from the MOCA Defense Taskforce, insights on regulatory developments, and opportunities to stay informed, get involved, and support this critical industry effort.



Chris Goeloe

PMA Director & EHS Committee Co-Chair
Anderson Development Company

Sound science is key in defending MOCA during the TSCA Risk Evaluation process. While PMA has generated significant data, further toxicology and industrial hygiene work is necessary. Additional funding is required to support these activities.

PMA TSCA MOCA Taskforce meeting with the US Environmental Protection Agency

By Chris Goeloe, EHS Committee Co-Chair

What happened?

On June 25th, the **PMA TSCA MOCA Taskforce had a productive meeting with the US Environmental Protection Agency in Washington, DC.** This included a presentation by PMA's toxicology consultant, Dr. Janet Anderson, from Exponent. Dr. Anderson provided a summary of the PMA TSCA 8(d) submission including unpublished health and safety studies which were favorable for MOCA and worker urinalysis data showing a reduction in MOCA exposure over time. Dr. Anderson also reviewed a proposed MOCA dermal absorption study that PMA plans to commission. Piper Howell discussed a proposed task-based worker MOCA exposure study. Chris Goeloe presented a case study of overreporting of MOCA emissions on the EPA Toxic Release Inventory. EPA was very engaged and there was a good dialogue.

Who was there?

This is the team that represented PMA: Chris Goeloe and Mike Kocak, EHS Co-Chairs; Paul Waite, Government Affairs Chair; Piper Howell and Robert

Czeizperger, Advocacy Co-Chairs; Paul Salamon, Board President; and Don Gallo, Legal Counsel. **PMA met with the EPA TSCA Existing Chemicals Risk Assessment Division and the Existing Chemicals Risk Management Division.** These are the groups that are responsible for assessing MOCA in the current Risk Evaluation stage and the last stage of Risk Management.

Why it matters?

It is important to talk directly with the staff at EPA who are evaluating MOCA in the TSCA Risk Evaluation stage to ensure the best available science provided by PMA can help inform the risk assessment process. **Engaging directly with the decision makers helps increase the probability of a positive outcome at the end of the review process.** And we asked Dr. Anderson to present on behalf of PMA since she has experience in this process and speaks the same language as EPA.

What is next?

PMA and Dr. Anderson have follow-up communications planned with EPA. We need input from EPA to ensure that our planned studies meet their expectations so the data will inform EPA's risk assessment.

Our Industry Is at Risk - Time Is Running Out



Paul Waite

PMA Director & Government Affairs Committee Chair
Era Polymers Corporation

It was a pleasure to connect with so many longtime colleagues and friends in Québec City while also welcoming a number of new attendees to the discussion. The energy, engagement, and enthusiasm surrounding the work the PMA and MOCA stakeholders have accomplished thus far were truly inspiring. The collective commitment to protecting the future of our industry was evident throughout the conference.

The Department of Defense has been clear in its request for assistance in mapping the supply chain for products containing 4,4'-methylenebis(2-chloroaniline) (MOCA). This effort is critical to demonstrating the important role MOCA plays in supporting U.S. national defense capabilities, energy infrastructure, and other essential manufacturing applications. With your assistance, we can help ensure decision-makers have a complete understanding of the material's importance to these critical sectors.

If you have information that may assist with this effort, please contact PMA legal counsel, Don Gallo, who can connect you with the appropriate parties and ensure the information is provided through the proper channels.

At the same time, the proposed dermal exposure study remains a critical component of our scientific and regulatory strategy. Generating accurate absorption-rate data is essential to ensuring that future epidemiological models and risk assessments are based on sound science rather than assumptions. Your continued support will help provide the exposure data needed for the ongoing TSCA evaluation and strengthen the industry's ability to advocate for science-based regulatory decisions.

Thank you for your continued engagement, support, and willingness to contribute. Together, we can help ensure that policymakers have the information necessary to make informed decisions regarding this critical material and its role in supporting American manufacturing, energy, and national security.

Please give today. The cost of inaction will be far greater than the cost of defense.

Contribute Funds Today



PMA Polyurethane Manufacturers Association

Help defend MOCA
Be part of the solution

Fundraising Goal: \$2 Million
Over 5-years (2025-2030)

PMA is proactively engaging scientific, regulatory, and legal experts to present accurate data, support informed decision-making, and advocate for the safe and responsible use and accessibility of MOCA

The time to act is NOW!

CONTRIBUTE FUNDS TODAY!



Contact the PMA office at 414-431-3094 or info@pmahome.org with any questions.

PMA Polyurethane Manufacturers Association

Our strengths. Your gains.



Polyurethane Manufacturers Association | 6737 West Washington Street Suite 4270 | Milwaukee, WI 53214 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!